Restricted accessResearch articleFirst published online 2010-8
Serum High-Sensitivity C-Reactive Protein and Homocysteine Changes During Hormonal Therapy in Women With Polycystic Ovary Syndrome: A Prospective,Matched Study
The study evaluated the effect of 5 hormonal regimes on serum levels of high-sensitivity C-reactive protein (hsCRP) and homocysteine (Hcy) in women with polycystic ovary syndrome (PCOS). Women with PCOS received (1) conjugated estrogens and cyproterone acetate (n = 22), (2) 17β-estradiol and cyproterone acetate (n = 17), (3) ethinyl-estradiol and cyproterone acetate (high dose; n = 20), (4) ethinyl-estradiol plus cyproterone acetate (low dose; n = 12), or (5) ethinyl-estradiol plus desogetrel (n = 12). Both hsCRP and Hcy levels were measured at baseline and after 4, 7, and 12 months. The 17β-estradiol/cyproterone acetate regime resulted in significant reduction of both hsCRP and Hcy levels (P < .001). The other 4 regimes only resulted in a reduction of Hcy levels (P < .001). In conclusion, the 17β-estradiol/cyproterone acetate regime had the most favorable effects in women with PCOS regarding serum levels of hsCRP and Hcy.
The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41-47.
2.
Royal College of Obstetricians and Gynaecologists.Green-top Guideline no. 33: long term consequences of polycystic ovary syndrome . December 2007.
3.
Ridker PMC-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21(3):315-325.
4.
Joseph J., Joseph L.Hyperhomocysteinemia and cardiovascular disease: new mechanisms beyond atherosclerosis . Metab Syndr Relat Disord. 2003;1(2):97-104.
5.
Bickerton AS, Clark N. et al. Cardiovascular risk in women with polycystic ovary syndrome (PCOS) . J Clin Pathol2005;58(2): 151-4.
6.
Kelly CC, Lyall H., Petrie JR, Gould GW, Connell JM, Sattar N.Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(6): 2453-2455.
7.
Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovaries syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160-2165.
8.
Morin-Papunen L., Rautio K., Ruokonen A., Hedberg P., Puukka M., Tapanainen JSMetformin reduces C-reactive protein levels in women with polycystic ovaries syndrome. J Clin Endocrinol Metab. 2003;88(10):4649-4654.
9.
Möhlig M., Spranger J., Osterhoff M., et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol. 2004;150(4):525-532.
10.
Gonzalez F. , Rote NS, Minium J., Kirwan JPEvidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism. 2009 ;58(7):954-962.
11.
Kaya C., Akgül E., Pabuccu R.C-reactive protein and homocysteine levels are associated with abnormal heart rate recovery in women with polycystic ovary syndrome. Fertil Steril. 2009, Apr 9. [Epub ahead of print].
12.
Ruan X., Dai Y.Study on chronic low-grade inflammation and influential factors of polycystic ovary syndrome. Med Princ Pract.2009;18(2):118-122.
13.
Rajendran S. , Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects . Atherosclerosis.2009; 204(2):509-514.
14.
Kaya C., Erkan AF, Cengiz SD, Dünder I., Demirel OE, Bilgihan A.Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril.2009; 92(4):1372-1377.
15.
Costa LO, dos Santos MP, Oliveira M., Viana A.Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome. Diabetes Res Clin Pract. 2008;81(2):179-183.
16.
Karadeniz M. , Erdogan M, Tamsel S., et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes . 2008;116(4):231-235.
17.
Erdogan M., Karadeniz M., Alper GE, et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes.2008;116(3): 143-147.
18.
Wu Y., Zhang J., Wen Y., Wang H., Zhang M., Cianflone K.Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril . 2009;91(1):213-219.
19.
Meden-Vrtovec H., Vrtovec B., Osredkar J.Metabolic and cardiovascular changes in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2007;99(2):87-90.
20.
Guzelmeric K., Alkan N., Pirimoglu M., Unal O., Turan C.Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol. 2007;23(9):505-510.
21.
Moran LJ, Noakes M., Clifton PM, Wittert GA, Belobrajdic DP, Norman RJC-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab . 2007;92(8):2944-2951.
22.
Nasiek M., Kos-Kudla B., Ostrowska Z., et al. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology. 2007;14(1):23-28.
23.
Engin-Ustün Y., Ustün Y., Meydanli MM, Kafkasli A., Yetkin G.Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome?Gynecol Endocrinol . 2006;22(6): 324-328.
24.
Diamanti-Kandarakis E., Paterakis T., Alexandraki K., et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006;21(6): 1426-1431.
25.
Erdogan M., Karadeniz M., Alper GE, et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes.2008;116(3): 143-147.
26.
Thomson R., Buckley J., Moran L., et al. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG.2009;116(9): 1242-1250.
27.
Jakubowska J., Bohdanowicz-Pawlak A., Milewicz A., Szymczak J., Bednarek-Tupikowska G., Demissie M.Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol.2008;24(7):378-384.
28.
Bahceci M., Aydemir M., Tuzcu A.Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril. 2007;87(6):1363-1368.
29.
Pamuk BO, Torun AN, Kulaksizoglu M., et al. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship with metabolic parameters. Fertil Steril. 2008, Dec 22. [Epub ahead of print].
30.
Soares GM, Vieira CS, Martins WP, et al. Increased arterial stiffness in non-obese women with polycystic ovary syndrome without co-morbidities: one more characteristic inherent to the syndrome?Clin Endocrinol (Oxƒ ). 2009;71(3):406-411.
31.
Oktem M., Ozcimen EE, Uckuyu A., et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril.2009; 91(6):2545-2550.
32.
Arikan S., Akay H., Bahceci M., Tuzcu A., Gokalp D.The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function. Fertil Steril.2009;91(2):450-455.
33.
Topcu S., Caliskan M., Ozcimen EE, et al. Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease? Hum Reprod. 2006;21(4):930-935.
34.
Yilmaz M., Biri A., Bukan N., et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polysystic ovaries syndrome. Gynecol Endocrinol . 2005;20(5):258-263.
35.
Bayraktar F. , Dereli D., Ozgen AG, Yilmaz C.Plasma homocysteine levels in polycystic ovaries syndrome and congenital adrenal hyperplasia. Endocr J. 2004;51(6):601-608.
36.
Schachter M. , Raziel A., Friedler S., Strassburger D., Bern O., Ron-El R.Insulin resistance in polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod . 2003; 18(4):721-727.
37.
Vrbıkova J., Tallova J., Bicikova M., Dvorakova K., Hill M., Starka L.Plasma thiols and levels in polycystic ovary syndrome. Clin Chem Lab Med.2003;41(2):216-221.
38.
Loverro G., Lorusso F., Mei L., Depalo R., Cormio G., Selvaggi L.The plasma homocysteine levels are increased in polycystic ovary syndrome . Gynecol Obstet Invest. 2002;53(3):157-162.
39.
Nafiye Y., Sevtap K., Muammer D., Emre O., Senol K., Leyla M.The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril.2009, Jan 24. [Epub ahead of print].
40.
Battaglia C. , Mancini F., Cianciosi A., et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol . 2008;111(2 pt 1):385-395.
41.
Atamer A., Demir B., Bayhan G., Atamer Y., Ilhan N., Akkus Z.Serum levels of leptin and homocysteine in women with polycystic ovary syndrome and its relationship to endocrine, clinical and metabolic parameters. J Int Med Res.2008; 36(1):96-105.
42.
de la Calle M., Gallardo T., Diestro MD, Hernanz A., Pérez E., Fernandez-Miranda C.Increased homocysteine levels in polycystic ovary syndrome [in Spanish]. Med Clin (Barc). 2007;129(8): 292-294.
43.
Badawy A., State O., El Gawad SSh, El Aziz OAPlasma homocysteine and polycystic ovary syndrome: the missed link. Eur J Obstet Gynecol Reprod Biol.2007;131(1):68-72.
44.
Bickerton AS , Clark N., Meeking D., et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58(2):151-154.
45.
Mancini F., Cianciosi A., Reggiani GM, Facchinetti F., Battaglia C., de Aloysio D.Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril.2009;91(6):2537-2544.
46.
Cagnacci A. , Tirelli A., Renzi A., Paoletti AM, Volpe A.Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception. 2006; 73(4):348-351.
47.
Prelevic GM , Kwong P., Byrne DJ, Jagroop IA, Ginsburg J., Mikhailidis DPA cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril. 2002;77(5):945-951.
48.
Stojanovic ND, Kwong P., Byrne DJ, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology. 2003; 54(4):391-399.
49.
Gul OB, Somunkiran A., Yucel O., Demirci F., Ozdemir I.The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2008;277(1):25-30.
50.
Vrbıkova J., Bicıkova M., Tallova J., Hill M., Starka L.Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome . Exp Clin Endocrinol Diabetes. 2002; 110(2):74-76.
51.
Luque-Ramırez M., Mendieta-Azcona C., del Rey Sanchez JM, Matıes M., Escobar-Morreale HFEffects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol . 2009;160(3):469-480.
